Daniel Aghion - 31 Dec 2025 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting relationship: Director
Issuer ticker: ORMP
Reported as of: 31 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jan 2026, 20:02:47 UTC
Prior SEC filing: 09 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Daniel Aghion

Key filing fact

Daniel Aghion filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 02 Jan 2026.

Key facts

This page summarizes Daniel Aghion's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 Jan 2026, 20:02.

Change

Previous filing in this sequence was filed on 09 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002004805 Primary reporting owner

Aghion Daniel

Relationship: Director
Address: 1185 AVENUE OF THE AMERICAS, NEW YORK
Signature: /s/ Daniel Aghion
Signature date: 02 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %: +39%
Price
Shares after: 107,191
Date: 31 Dec 2025
Ownership: Direct
Footnotes: F1

ORMP transaction

Common Stock

Award

Transaction value
Shares: +6,250
Change %: +5.8%
Price
Shares after: 113,441
Date: 31 Dec 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.

Footnote F2

Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.